• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病患者慢性肾脏病的发展:一项队列研究。

Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study.

机构信息

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea.

出版信息

J Hepatol. 2017 Dec;67(6):1274-1280. doi: 10.1016/j.jhep.2017.08.024. Epub 2017 Sep 20.

DOI:10.1016/j.jhep.2017.08.024
PMID:28870674
Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) has been associated with chronic kidney disease (CKD), but cohort studies are limited. We investigated the longitudinal association of NAFLD and its severity with the development of CKD.

METHODS

We performed a retrospective cohort study of 41,430 adult men and women (average age, 48.9y) without CKD at baseline who underwent repeated health check-up examinations from January 1, 2003, through December 31, 2013. NAFLD status was assessed by ultrasonography, and NAFLD severity was assessed by the NAFLD fibrosis score (NFS).

RESULTS

The outcome was an incident CKD, defined as an estimated glomerular filtration rate less than 60ml/min/1.73m. During 200,790 person-years of follow-up (median follow-up of 4.15years), we identified 691 incident CKD cases. The multivariable-adjusted hazard ratio for CKD comparing participants with and without NAFLD was 1.22 (95% confidence interval [CI] 1.04-1.43). The risk of CKD increased progressively with increased NAFLD severity. The multivariable-adjusted hazard ratios for CKD comparing participants with NFS <-1.455 and those with NFS ≥-1.455 to participants without NAFLD were 1.09 (95% CI 0.91-1.32) and 1.58 (95% CI 1.30-1.92), respectively. The association was consistent across clinically relevant subgroups.

CONCLUSION

In a large cohort of adult men and women without CKD, NAFLD was associated with an increased risk of CKD development. NAFLD may adversely affect renal function and patients may need to be carefully monitored for an increased risk of CKD.

LAY SUMMARY

The presence of fatty liver is associated with the future decline of renal function. Thus, fatty liver patients need to be monitored regularly for renal function.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)与慢性肾脏病(CKD)相关,但队列研究有限。我们研究了 NAFLD 及其严重程度与 CKD 发展的纵向关联。

方法

我们对 2003 年 1 月 1 日至 2013 年 12 月 31 日期间未患有 CKD 的 41430 名成年男女进行了回顾性队列研究(平均年龄为 48.9 岁),这些人接受了重复的健康检查。NAFLD 状态通过超声检查评估,NAFLD 严重程度通过 NAFLD 纤维化评分(NFS)评估。

结果

结局是新发 CKD,定义为估计肾小球滤过率小于 60ml/min/1.73m。在 200790 人年的随访期间(中位随访时间为 4.15 年),我们发现了 691 例新发 CKD 病例。与无 NAFLD 者相比,NAFLD 患者发生 CKD 的多变量调整后的危险比为 1.22(95%置信区间 [CI] 1.04-1.43)。随着 NAFLD 严重程度的增加,CKD 的风险逐渐增加。与 NFS <-1.455 的参与者相比,与 NFS ≥-1.455 的参与者相比,NFS 为-1.455 的参与者发生 CKD 的多变量调整后的危险比分别为 1.09(95%CI 0.91-1.32)和 1.58(95%CI 1.30-1.92)。该关联在临床相关亚组中一致。

结论

在没有 CKD 的大量成年男女队列中,NAFLD 与 CKD 发展风险增加相关。NAFLD 可能对肾功能产生不利影响,患者可能需要密切监测 CKD 风险增加的情况。

非专业人士翻译,仅供参考。

相似文献

1
Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study.非酒精性脂肪性肝病患者慢性肾脏病的发展:一项队列研究。
J Hepatol. 2017 Dec;67(6):1274-1280. doi: 10.1016/j.jhep.2017.08.024. Epub 2017 Sep 20.
2
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.非酒精性脂肪性肝病增加了慢性肾脏病发病的风险:系统评价和荟萃分析。
Metabolism. 2018 Feb;79:64-76. doi: 10.1016/j.metabol.2017.11.003. Epub 2017 Nov 11.
3
Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.美国非酒精性脂肪肝成人中的非侵入性纤维化标志物与慢性肾脏病
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):404-410. doi: 10.1097/MEG.0000000000001045.
4
The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study.在一项为期10年的前瞻性队列研究中,脂肪肝指数作为新发慢性肾脏病的预测指标。
PLoS One. 2017 Jul 24;12(7):e0180951. doi: 10.1371/journal.pone.0180951. eCollection 2017.
5
Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study.非酒精性脂肪性肝病加速慢性肾脏病患者肾功能下降:一项队列研究。
Sci Rep. 2018 Mar 16;8(1):4718. doi: 10.1038/s41598-018-23014-0.
6
New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease.新的非酒精性脂肪性肝病和纤维化进展与慢性肾脏病发病风险相关。
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3957-e3968. doi: 10.1210/clinem/dgab425.
7
Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.非酒精性脂肪性肝病与慢性肾脏病的临床转归。
Nephrol Dial Transplant. 2019 Mar 1;34(3):449-457. doi: 10.1093/ndt/gfx381.
8
Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.非酒精性脂肪性肝病增加了发生进展性慢性肾脏病的风险:一项倾向评分匹配队列研究。
J Intern Med. 2019 Dec;286(6):711-722. doi: 10.1111/joim.12964. Epub 2019 Aug 23.
9
Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults on their health check-up.中国成年人健康体检中无创诊断的肝脂肪变性与慢性肾脏病之间的关联
J Dig Dis. 2017 Apr;18(4):229-236. doi: 10.1111/1751-2980.12465.
10
Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes.非酒精性脂肪性肝病与 1 型糖尿病患者慢性肾脏病的发生率增加独立相关。
Diabetes Care. 2014 Jun;37(6):1729-36. doi: 10.2337/dc13-2704. Epub 2014 Apr 2.

引用本文的文献

1
The newly proposed dietary index for gut microbiota and its association with the risk of nonalcoholic fatty liver disease: the mediating role of body mass index.新提出的肠道微生物群饮食指数及其与非酒精性脂肪性肝病风险的关联:体重指数的中介作用。
Diabetol Metab Syndr. 2025 Jun 21;17(1):237. doi: 10.1186/s13098-025-01801-w.
2
Synergistic impact of serum uric acid and ferritin on MAFLD risk: A comprehensive cohort analysis.血清尿酸和铁蛋白对MAFLD风险的协同影响:一项综合队列分析。
Sci Rep. 2025 May 29;15(1):18936. doi: 10.1038/s41598-025-02914-y.
3
Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review.
MAFLD/NAFLD背景下的肾脏、肺部和皮肤并发症:一项叙述性综述
Metabolites. 2025 Apr 14;15(4):272. doi: 10.3390/metabo15040272.
4
Transition from acute kidney injury to chronic kidney disease in liver cirrhosis patients: Current perspective.肝硬化患者急性肾损伤向慢性肾脏病的转变:当前观点
World J Nephrol. 2025 Mar 25;14(1):102381. doi: 10.5527/wjn.v14.i1.102381.
5
Non-obese non-alcoholic fatty liver disease and the risk of chronic kidney disease: a systematic review and meta-analysis.非肥胖型非酒精性脂肪性肝病与慢性肾脏病风险:一项系统评价与荟萃分析
PeerJ. 2024 Dec 17;12:e18459. doi: 10.7717/peerj.18459. eCollection 2024.
6
Association between liver fat level and risk of hypertension: evidence from a Chinese health examination dataset.肝脏脂肪水平与高血压风险的关联:来自中国体检数据集的证据。
J Hypertens. 2024 Oct 1;42(10):1785-1794. doi: 10.1097/HJH.0000000000003803. Epub 2024 Jun 25.
7
Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.代谢功能障碍相关脂肪性肝病、慢性肾脏病与腹型肥胖之间的关联:一项全国性回顾性队列研究。
Sci Rep. 2024 Jun 2;14(1):12645. doi: 10.1038/s41598-024-63386-0.
8
Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease.肝脂肪变性与血压升高之间的时间关系及其在心血管疾病发展中的中介作用。
Hypertens Res. 2024 Jul;47(7):1811-1821. doi: 10.1038/s41440-024-01708-5. Epub 2024 May 17.
9
Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.在患有代谢功能障碍相关脂肪性肝病合并肝纤维化的患者队列中,慢性肾脏病和死亡率的风险增加。
PLoS One. 2024 Apr 16;19(4):e0299507. doi: 10.1371/journal.pone.0299507. eCollection 2024.
10
The Fatty Liver Index's Association with Incident Chronic Kidney Disease in Korean Middle-Aged Adults: A Community-Based Cohort Study.韩国中年成年人中脂肪肝指数与慢性肾脏病发病的关联:一项基于社区的队列研究
J Clin Med. 2024 Mar 12;13(6):1616. doi: 10.3390/jcm13061616.